Identification and SAR exploration of a novel series of Legumain inhibitors

  • Bioorg Med Chem Lett. 2019 Jun 15;29(12):1546-1548. doi: 10.1016/j.bmcl.2019.03.019.
Sharon L Eddie  1 Aaron Gregson  1 Emma Graham  1 Stephanie Burton  2 Timothy Harrison  2 Roberta Burden  3 Christopher J Scott  3 Paul B Mullan  1 Rich Williams  4
Affiliations
  • 1. CCRCB Drug Discovery Group, Centre for Cancer Research and Cell Biology, Queen's University Belfast, 97 Lisburn Rd., Belfast BT9 7BL, United Kingdom.
  • 2. Almac Discovery, Health Sciences Building, Queen's University Belfast, 97 Lisburn Rd., Belfast BT9 7AE, United Kingdom.
  • 3. School of Pharmacy, Queen's University Belfast, 97 Lisburn Rd., Belfast BT9 7BL, United Kingdom.
  • 4. CCRCB Drug Discovery Group, Centre for Cancer Research and Cell Biology, Queen's University Belfast, 97 Lisburn Rd., Belfast BT9 7BL, United Kingdom. Electronic address: [email protected].
Abstract

This letter describes the development of a series of potent and selective small molecule Legumain inhibitors suitable as chemical probes for in vitro experiments. Our previous research had identified a dipeptide inhibitor utilizing a semi-reversible cyano warhead that generated 2, a cell active inhibitor. This work explores an alternative P2-P3 linker and further SAR exploration of the P3 group which led to the identification of 16i, a highly potent inhibitor with excellent physiochemical properties.

Keywords
Legumain; SAR; Small molecule inhibitor.
Products